Skip to main content
MediPharm Labs Corp. logo

MediPharm Labs Corp. — Investor Relations & Filings

Ticker · LABS LEI · 875500SIGS9KXW34K754 TSX Manufacturing
Open in API
Filings indexed 458 across all filing types
Latest filing 2026-05-20 Proxy Solicitation & In…
Country CA Canada
Listing TSX LABS

About MediPharm Labs Corp.

https://medipharmlabs.com/

MediPharm Labs Corp. is a full-service pharmaceutical company specializing in the development, formulation, processing, packaging, and distribution of precision-based, advanced cannabinoid products. Operating from Good Manufacturing Practices (GMP) certified facilities, the company focuses on producing pharma-quality cannabis Active Pharmaceutical Ingredients (API), concentrates, and derivative products. Utilizing strict manufacturing standards and ISO standard cleanrooms, MediPharm Labs ensures its offerings are pure, trusted, and precisely dosable for patients and consumers. Services include wholesale and white label platforms for domestic and international clients. The company holds a Pharmaceutical Drug Establishment License, enabling the manufacture of pharmaceutical drugs containing cannabis.

Recent filings

Filing Released Lang Actions
Certificate re dissemination to shareholders.pdf
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a TSX Trust notification confirming that proxy-related materials (proxy, notice-and-access notice, voting instruction form, information circular, meeting guide) were mailed to securityholders. This clearly pertains to distribution of proxy solicitation materials to shareholders. Under our taxonomy, such materials and their distribution fall under Proxy Solicitation & Information Statement (PSI), not a financial report or earnings release. Therefore, the correct classification is PSI.
2026-05-20 English
News release - English.pdf
Earnings Release Classification · 90% confidence The document is a press release announcing the company’s first quarter 2026 financial results, including key highlights such as revenue, adjusted EBITDA, gross margins, and conference call details. It does not contain full financial statements as required for an Interim/Quarterly Report (IR), nor is it a transcript or regulatory filing. This matches an initial earnings release format. Therefore, the correct classification is Earnings Release (ER). Q1 2026
2026-05-13 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 98% confidence The document is a Form 52-109F2 officer certification attesting to the interim financial report and MD&A. It contains no substantive financial data itself, only the CFO’s attestation as required under Canadian securities rules. Under the Certification Rule, such attestations are classified as Regulatory Filings (RNS), not as the interim report itself.
2026-05-13 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a full set of condensed interim consolidated financial statements for the three months ended March 31, 2026 and 2025, including financial position, loss, cash flows, equity changes, and detailed notes. It contains substantive financial statements for a period shorter than a full fiscal year (a quarter). Therefore, it meets the criteria for an Interim/Quarterly Report rather than a simple earnings release or notice. It is not merely an announcement or a certification. Accordingly, it is classified as an Interim/Quarterly Report (IR). Q1 2026
2026-05-13 English
News release - English.pdf
Earnings Release Classification · 95% confidence The document is a press release announcing the date when MediPharm Labs will report its first quarter 2026 financial results and the details of the upcoming conference call and webcast. It does not contain the actual financial results or substantive financial data but rather informs investors about the timing and logistics of the earnings release and conference call. The document length is 5629 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself. Therefore, the appropriate classification is Earnings Release (ER), as it is the initial announcement of quarterly financial results and related conference call information. Q1 2026
2026-05-08 English
News release - English.pdf
Regulatory Filings
2026-04-28 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.